Acute Repetitive Seizures Market - By Drug Class (Benzodiazepines, lorazepam, Diazepam, Midazolam), By Route of Administration (Oral, Intramuscular, Intranasal, Buccal, Rectal), By Distribution Channel (Hospital Pharmacy, Specialty Clinic Pharmacies, Online Stores) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 185
Status: Published
Report Code: ARI100371
Acute Repetitive seizures are also called recurrent, serial, cluster, crescendo seizures. The Features of Acute repetitive seizures include multiple seizures (more than 3) in less than 24 hours. However, the prevalence of acute Repetitive seizures is not known. Acute repetitive seizure occurs due to unusual activities in the brain which may go unseen or it may cause convulsions and unconsciousness due to uncontrolled body shakes. Acute repetitive seizures include many types of epileptic seizures and can develop at any stage and any age. The caretakers or the prescriber should be comfortable and experienced so that they can treat the patient effectively. The caretakers should have should have a plan for their treatment after they observe the behaviour of the patient. The most approved treatment for acute repetitive seizures is rectal diazepam gel but due to its route of administration it may be inconvenient and embarrassing in social settings. Also, the treatments can cause depression in nervous system. The seizures can be caused due to head injuries, brain tumours, withdrawal from some medicines, use of narcotics and brain infections. Moreover, several other routes for acute repetitive seizures have been approved such as intranasal administration which provides fast absorption.
High unmet clinical needs for patients, as well as caregivers, and availability of advanced product pipeline are some of the major factors expected to propel market growth. Drug therapy is effective for most of the patients suffering from cluster seizures. However, there are a significant number of treatment challenges and unmet medical needs including drug induced seizures, adverse reactions, and lack of antiepileptogenic agents that can prevent development of seizures and its comorbidities.
Major market members in the Global Acute Repetitive Seizure Market identified across the value chain include, Valeant Pharmaceuticals, Alexza Pharmaceuticals, Veriton Pharma Limited, Sanofi, Pfizer Inc., Neurelis, UCB S.A., Neurelis, Inc and others. Also, there are many emerging therepies from manufacturers such as Acorda Therapeutics, Inc., Upsher-Smith Laboratories, LLC, Epalex and others.
Analyst Commentary
Global Acute Repetitive Seizure Market has witnessed growth due to increasing incidents of epilepsy with approximately 3.4 million people suffering from the disorder. According to Centre for Disease Control and Prevention about 470,000 children and 3 million U.S. adults were suffering from epilepsy. Increasing unmet demands for caretakers and patients will increase the demand for acute repetitive seizure treatment market. Also continuous research and development and progressive product pipeline are some of the major factors which are predicted to drive the industry development. However there are a lot of challenges which are hampering the treatment market for acute repetitive seizures such as adverse reactions caused due to the drugs, drug induced seizures. These factors are preventing the growth of acute repetitive seizure market. Shorter hospital stays, progression in the treatment methods, low prices for the drugs and healthcare insurance facilities are expected to drive the repetitive seizure market.
In an attempt to curb healthcare expenditure, governments across the globe are making continuous efforts to reduce hospital stays and on-site patient treatment costs through outpatient care models, such as clinic and home healthcare. Emerging economies like India and China are increasingly implementing these healthcare reforms. This factor is expected to propel the growth of acute repetitive seizures market.
The treatment gap is a useful measure to compare access to quality care for patients suffering from seizures. The treatment gap for low- and middle-income countries, such as India, South Africa, and Brazil, is around 80%, while it is around 60% in developed countries, such as U.S. and U.K.
Among the many routes of medicine administration, patients prefer intranasal route over other types, such as buccal, rectal, and intramuscular route. Parenteral medications have proven to be the optimal option for outpatient treatment. However, in some countries, such as Netherlands, caregivers are not qualified for administrating parenteral medications.
UCB S.A. and Neurelis, Inc. are likely to hold the major share of the global market due to the commercialization of USL-261 and VALTOCO. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the prices will be usually high. In addition, as per our studies, the preferred route of administration is nasal, which in turn will result into higher adoption of these two drugs.
Segmentation
Geographically, global Acute Repetitive seizure Market is classified into regions viz. North America, Latin America, Asia Pacific, Middle East & Africa, Eastern Europe and Western Europe. North America’s Acute Repetitive seizure Market is growing due to the increasing incidence of acute repetitive seizures. Advancement and continuous progression in the development of new drugs is expanding the acute repetitive seizure treatment market. In developed countries such as U.S and Germany patient care is considered the top most priority. Positive government support with rising healthcare expenditure is expected to increase acute repetitive seizure market. Also Developing countries such as China and India are progressively caring out healthcare reforms which will further expand the market for acute repetitive seizure market.
Based on product, the market is categorized into USL-261, NRL-1, AZ-002, Diastat Rectal Gel {DRG}, and others. Diastat Rectal Gel led the product segment in 2017 owing to its efficiency and lack of FDA-approved drugs in the market. It is the only FDA-approved drug and the generic versions of it were introduced in 2010.
NRL-1 is expected to be the fastest-growing segment over the forecast period. It is an investigational drug developed by Neurelis to be used for children, adolescents, and adults. The company filed NDA with the FDA in September 2018. USL-261 is expected to show lucrative growth over the forecast years and is specifically designed for intranasal administration for outpatient use.
Tentatively, Acute Repetitive seizure Market has been segmented on the basis of product type, application, and end user. On the basis of Drug Class, Acute Repetitive seizure Market can be segmented as: Benzodiazepines, lorazepam, diazepam, midazolam. On the Basis of route of Administration, Acute Repetitive seizure Market can be segmented as: Oral, Intramuscular, Intranasal, Buccal, Rectal, On the Basis of Distribution channel, Acute Repetitive seizure Market can be segmented as: Hospital pharmacy, Specialty Clinic pharmacies, Online stores.
Increasing number of new drug applications and approvals are estimated to enhance the competitive environment of the acute repetitive seizure market in the next few years. For example, the company Neurelis received an FDA grant in 2015 and recently the company has submitted a new drug application VALTOCO for the treatment of acute repetitive seizure market.
The report provides in-depth, macro-economic indicators, analysis of parent market trends, governing factors along with market attractiveness in every segments. Also the report is a compilation of quantitative and qualitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report also outlines the qualitative impact of different market factors on market segments and geographies.
Regional Analysis
Regions include: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
U.S. held a share of 17.0% in 2017 in the global market. According to the data published by CDC, around 4.3 million adults and 750,000 children in U.S. had epilepsy in 2014. Also, the total direct and indirect cost of epilepsy in this region is estimated to be around USD 15.5 billion annually. Thus, presence of a large target population base for epilepsy drug in this region will spur the market growth.
Germany is expected to witness robust growth over the forecast period owing to technological advancements in scientific, clinical, and medical fields. Increasing demand for antiepileptic drugs due to rising disease prevalence in the region fosters the market growth. Government initiatives, in an attempt to improve the quality of life and awareness regarding the disease, coupled with promotion of better healthcare facilities are the major drivers boosting market growth in this region.
The Asia Pacific market is also likely to witness rapid development on account of increasing healthcare expenditure in developing countries, such as India and China. A huge gap was observed in the treatment for acute repetitive seizures in this region. Hence, the demand for the antiseizure drugs in these developing countries encourages a shift in market potential from the already saturated European and North American regions to such economies
al Analysis:
\"TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Acute Repetitive Seizures Market
Chapter 5. Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
5.1. Global Acute Repetitive Seizures Market Share, By Product Types, 2015 - 2027 (USD Million)
5.1.1. USL-261
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. NRL-1
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. AZ-002
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Diastat Rectal Ge
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.5. Others
5.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
6.1. Global Acute Repetitive Seizures Share, By Route of Administration, 2015 - 2027 (USD Million)
6.1.1. Oral
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Intramuscular
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Intranasal
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Buccal
6.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.5. Others
6.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Acute Repetitive Seizures Market Overview, By Geography, 2015 – 2027 (USD Million)
7.1. Global Acute Repetitive Seizures Market Share, By Geography, 2015 - 2027 (USD Million)
7.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 8. North America Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1. North America Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.2. North America Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
8.1.3. North America Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
8.1.4. North America Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
8.1.4.2. Canada Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
Chapter 9. Europe Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. Europe Global Acute Repetitive Seizures Market Overview, 2015 – 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.3. Europe Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4. Europe Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.1.3. Germany Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4.2. France
9.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.2.3. France Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4.3. UK
9.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.3.3. UK Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.4.3. Italy Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.5.3. Spain Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market size and projections, 2015 – 2025
9.1.4.6.2. Rest of Europe Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
9.1.4.6.3. Rest of Europe Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
Chapter 10. Asia Pacific Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.4.1.3. India Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.2.2. China Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.4.2.3. China Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.4.3.3. Japan Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.4.2. South Korea Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.4.4.3. South Korea Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
10.1.4.5.3. Rest of Asia Pacific Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
Chapter 12. South America Global Acute Repetitive Seizures Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Global Acute Repetitive Seizures Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. South America Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
12.1.3. South America Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
12.1.4. South America Global Acute Repetitive Seizures Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.4.1. Brazil
12.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.1.2. Brazil Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
12.1.4.1.3. Brazil Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
12.1.4.2. Argentina
12.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.2.2. Argentina Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
12.1.4.2.3. Argentina Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
12.1.4.3. Rest of South America
12.1.4.3.1. Market size and projections, 2015 – 2026
12.1.4.3.2. Rest of South America Global Acute Repetitive Seizures Market Overview, By Product Types, 2015 - 2027 (USD Million)
12.1.4.3.3. Rest of South America Acute Repetitive Seizures Market Overview, By Route of Administration, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Product Types development
Chapter 14. Key Route of Administration Analysis
14.1. Valeant Pharmaceuticals
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Types Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Valeant Pharmaceuticals
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Types Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Alexza Pharmaceuticals
14.4. Veriton Pharma Limited.
14.5. Acute Repetitive Seizures
14.6. Sanofi.
14.7. Neurelis
14.8. UCB S.A
Chapter 15. Global Acute Repetitive Seizures Market Cost Analysis
15.1. Global Acute Repetitive Seizures Market Key Raw Materials Analysis
15.1.1. Key Raw Materials
15.1.2. Price Trend of Key Raw Materials
15.1.3. Key Suppliers of Raw Materials
15.1.4. Market Concentration Rate of Raw Materials
15.2. Proportion of Wing Cost Structure
15.2.1. Raw Materials
15.2.2. Labor Cost
15.2.3. Wing Expenses
15.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 16. Chain, Sourcing Strategy and Downstream Buyers
16.1. Global Acute Repetitive Seizures Market Chain Analysis
16.2. Upstream Raw Materials Sourcing
16.3. Raw Materials Sources of Global Acute Repetitive Seizures Market Major Manufacturers in 2019
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Electrical Damage
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Product Types Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Product Types Progress in Related Industry
18.2. Oncology Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Acute Repetitive Seizures Market share, by Product Types, 2020 & 2027 (%)
10. Global Acute Repetitive Seizures Market share, by Product Types 2020 & 2027 (USD Million)
11. Global Acute Repetitive Seizures Market share, by USL-261, by Product Types, 2020 & 2027 (USD Million)
12. Global Acute Repetitive Seizures Market share, by NRL-1, by Product Types, 2020 & 2027 (USD Million)
13. Global Acute Repetitive Seizures Market share, by AZ-002, by Product Types, 2020 & 2027 (USD Million)
14. Global Acute Repetitive Seizures Market share, by Diastat Rectal Ge, by Product Types, 2020 & 2027 (USD Million)
15. Global Acute Repetitive Seizures Market share, by Others, by Product Types, 2020 & 2027 (USD Million)
16. Global Acute Repetitive Seizures Market share, by Route of Administration, 2020 & 2027 (%)
17. Global Acute Repetitive Seizures Market share, by Oral, by Route of Administration, 2020 & 2027 (USD Million)
18. Global Acute Repetitive Seizures Market share, by Intramuscular, by Route of Administration, 2020 & 2027 (USD Million)
19. Global Acute Repetitive Seizures Market share, by Intranasal, by Route of Administration, 2020 & 2027 (USD Million)
20. Global Acute Repetitive Seizures Market share, by Buccal, by Route of Administration, 2020 & 2027 (USD Million)
21. Global Acute Repetitive Seizures Market share, by Others, by Route of Administration, 2020 & 2027 (USD Million)
22. Global Acute Repetitive Seizures Market share, by Type of Synthesis, 2020 & 2027 (%)
23. Global Acute Repetitive Seizures Market share, by Synthetic API, by Type of Synthesis, 2020 & 2027 (USD Million)
24. Global Acute Repetitive Seizures Market share, by Biotic API, by Type of Synthesis, 2020 & 2027 (USD Million)
25. Global Acute Repetitive Seizures Market share, by region, 2020 - 2027(%)
26. Global Acute Repetitive Seizures Market share, by region, 2019 - 2027(USD Million)
27. North America Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
28. North America Global Acute Repetitive Seizures Market share, by Countries, 2020 & 2027 (%)
29. U.S. Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
30. Canada Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
31. Europe Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
32. Europe Global Acute Repetitive Seizures Market share, by Countries, 2020 & 2027 (%)
33. Spain Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
34. UK Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
35. Italy Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
36. Germany Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
37. France Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
38. Rest of Europe Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
39. Asia-Pacific Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
40. Asia-Pacific Global Acute Repetitive Seizures Market share, by Countries, 2020 & 2027 (%)
41. China Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
42. India Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
43. Australia Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
44. Japan Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
45. Rest of Asia-Pacific Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
46. Middle East & Africa Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
47. Middle East & Africa Global Acute Repetitive Seizures Market share, by Countries, 2020 & 2027 (%)
48. GCC Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
49. South Africa Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
50. Rest of Middle East & Africa Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
51. South America Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
52. Brazil Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
53. Mexico Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
54. Argentina Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
55. Rest Of South America Global Acute Repetitive Seizures Market, 2020 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Acute Repetitive Seizures Market, 2020-2027 (USD Million)
4. Acute Repetitive Seizures requirement, by country, 2020-2027, (USD Million)
5. North America Acute Repetitive Seizures Market, by Product Types, 2020-2027 (USD Million)
6. North America Acute Repetitive Seizures Market, by Route of Administration, 2020-2027 (USD Million)
7. Europe Acute Repetitive Seizures Market, by Product Types, 2020-2027 (USD Million)
8. Europe Acute Repetitive Seizures Market, by Route of Administration, 2020-2027 (USD Million)
9. Asia Pacific Acute Repetitive Seizures Market, by Product Types, 2020-2027 (USD Million)
10. Asia Pacific Acute Repetitive Seizures Market, by Route of Administration, 2020-2027 (USD Million)
11. Middle East & Africa Global Acute Repetitive Seizures Market, by Product Types, 2020-2027 (USD Million)
12. Middle East & Africa Acute Repetitive Seizures Market, by Route of Administration, 2020-2027 (USD Million)
13. South America Acute Repetitive Seizures Market, by Product Types, 2020-2027 (USD Million)
14. South America Acute Repetitive Seizures Market, by Route of Administration, 2020-2027 (USD Million)
15. Global Acute Repetitive Seizures Market, Company Market Share, 2018 (%)
16. HEXAGON AB: Product Benchmarking
17. HEXAGON AB: Financial Performance
18. Valeant Pharmaceuticals: Product Benchmarking
19. Valeant Pharmaceuticals: Financial Performance
20. Alexza Pharmaceuticals: Product Benchmarking
21. Alexza Pharmaceuticals: Financial Performance
22. VERITON PHARMA LIMITED.: Product Benchmarking
23. VERITON PHARMA LIMITED.: Financial Performance
24. ACUTE REPETITIVE SEIZURES: Product Benchmarking
25. ACUTE REPETITIVE SEIZURES: Financial Performance
\"
The Leading Key Players in Acute Repetitive Seizures Market
value chain include
Valeant Pharmaceuticals
Alexza Pharmaceuticals
Veriton Pharma Limited
Sanofi
Pfizer Inc.
Neurelis
UCB S.A.
Neurelis
Inc Also
there are many emerging therepies from manufacturers such as Acorda Therapeutics Inc.
Upsher-Smith Laboratories LLC
Epalex
